Int J Biol Sci 2024; 20(1):200-217. doi:10.7150/ijbs.87820 This issue Cite

Research Paper

Treatment for type 2 diabetes and diabetic nephropathy by targeting Smad3 signaling

Huijun He1,2, Honglian Wang2, Xiaocui Chen2, Yu Zhong2, Xiao Ru Huang2, Ronald CW Ma2, Cheng Wang1✉, Hui-Yao Lan2✉

1. Division of Nephrology, Department of Medicine, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, 519000, China; Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province, 519000, China
2. Department of Medicine and Therapeutics, and Li Ka Shing Institute of Health Sciences, the Chinese University of Hong Kong, Hong Kong; and Guangdong-Hong Kong Joint Laboratory on Immunological and Genetic Kidney Diseases, and Departments of Nephrology and Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China.

Citation:
He H, Wang H, Chen X, Zhong Y, Huang XR, Ma RCW, Wang C, Lan HY. Treatment for type 2 diabetes and diabetic nephropathy by targeting Smad3 signaling. Int J Biol Sci 2024; 20(1):200-217. doi:10.7150/ijbs.87820. https://www.ijbs.com/v20p0200.htm
Other styles

File import instruction

Abstract

Graphic abstract

TGF-β/Smad3 signaling plays a critical role in type 2 diabetes (T2D) and type 2 diabetic nephropathy (T2DN), but treatment by specifically targeting Smad3 remains unexplored. To develop a new Smad3-targeted therapy for T2D and T2DN, we treated db/db mice at the pre-diabetic or established diabetic stage with a pharmacological Smad3 inhibitor SIS3. The therapeutic effect and mechanisms of anti-Smad3 treatment on T2D and T2DN were investigated. We found that anti-Smad3 treatment on pre-diabetic db/db mice largely attenuated both T2D and T2DN by markedly reducing blood glucose levels, and inhibiting the elevated serum creatinine, microalbuminuria, and renal fibrosis and inflammation. Unexpectedly, although SIS3 treatment on the established diabetic db/db mice inhibited T2DN but did not significantly improve T2D. Mechanistically, we uncovered that inhibition of T2DN in SIS3-treated db/db mice was associated with effectively restoring the balance of TGF-β/Smad signaling by inhibiting Smad3 while increasing Smad7, thereby suppressing Smad3-mediated renal fibrosis and NF-κB-driven renal inflammation via lncRNA Erbb4-IR and LRN9884-dependent mechanisms. We also revealed that inhibition of islet β cell injury by preventing the loss of islet Pax 6 could be the mechanism through which the pre-diabetic treatment, rather than the late SIS3 treatment on db/db mice significantly improved the T2D phenotype.

Keywords: Type-2 diabetes, Smad3 inhibitor, Treatment, Islet, Nephropathy


Citation styles

APA
He, H., Wang, H., Chen, X., Zhong, Y., Huang, X.R., Ma, R.CW., Wang, C., Lan, H.Y. (2024). Treatment for type 2 diabetes and diabetic nephropathy by targeting Smad3 signaling. International Journal of Biological Sciences, 20(1), 200-217. https://doi.org/10.7150/ijbs.87820.

ACS
He, H.; Wang, H.; Chen, X.; Zhong, Y.; Huang, X.R.; Ma, R.CW.; Wang, C.; Lan, H.Y. Treatment for type 2 diabetes and diabetic nephropathy by targeting Smad3 signaling. Int. J. Biol. Sci. 2024, 20 (1), 200-217. DOI: 10.7150/ijbs.87820.

NLM
He H, Wang H, Chen X, Zhong Y, Huang XR, Ma RCW, Wang C, Lan HY. Treatment for type 2 diabetes and diabetic nephropathy by targeting Smad3 signaling. Int J Biol Sci 2024; 20(1):200-217. doi:10.7150/ijbs.87820. https://www.ijbs.com/v20p0200.htm

CSE
He H, Wang H, Chen X, Zhong Y, Huang XR, Ma RCW, Wang C, Lan HY. 2024. Treatment for type 2 diabetes and diabetic nephropathy by targeting Smad3 signaling. Int J Biol Sci. 20(1):200-217.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image